Bibliographic citations
Davila, S., Mamani, S. (2015). Acetato de medroxiprogesterona y su relación con la obesidad en usuarias continuadoras. Hospital regional docente de Trujillo. Enero – Diciembre 2012 [Tesis, Universidad Privada Antenor Orrego]. https://hdl.handle.net/20.500.12759/1122
Davila, S., Mamani, S. Acetato de medroxiprogesterona y su relación con la obesidad en usuarias continuadoras. Hospital regional docente de Trujillo. Enero – Diciembre 2012 [Tesis]. PE: Universidad Privada Antenor Orrego; 2015. https://hdl.handle.net/20.500.12759/1122
@misc{renati/1346022,
title = "Acetato de medroxiprogesterona y su relación con la obesidad en usuarias continuadoras. Hospital regional docente de Trujillo. Enero – Diciembre 2012",
author = "Mamani Chullunquia, Sayda Claudia",
publisher = "Universidad Privada Antenor Orrego",
year = "2015"
}
This research titled, “medroxyprogesterone acetate and its relationship with obesity successors users. Regional Hospital of Trujillo, January to December 2012, aims to determine the relationship between the use of medroxyprogesterone acetate and obesity successors users of Trujillo Regional Teaching Hospital from January to December 2012. Taking as no type of study methodology experimental, correlational design, with the sample of 207 cases, a protocol in which variations in BMI was recorded in three, six, nine and twelve months was used. We conclude that the BMI at the beginning of the investigation was average with 55.56% in 115 patients and less with 0.48% with grade II obesity, at the end of year of use the body mass index showed a slight weight increase of 32.8% to 37.2% in the same way obesity grade I from 4.8% to 8.2% and decreasing the normal BMI of 55.6% to 50.2% weight gain according to the time of use was evident that most of the BMI increased 9 and 12 months, except in obesity I, the variation in weight within a year found that most fell more than 3 kg, followed that stayed the same and for which increased from 1 to 2 kg. You can also conclude that the greater weight gain occurs in women with a BMI of underweight with 4.3 kg followed by women with normal BMI with 2.6 Kg. Therefore we conclude that the use of medroxyprogesterone acetate in successors users of Regional Hospital has a relationship with obesity, the value of P <0.001. Keywords: Medroxyprogesterone Acetate BMI Obesity
This item is licensed under a Creative Commons License